Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
Status:
Suspended
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus
a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care
buprenorphine treatment for Opioid use disorder (OUD). Effects of adjunctive psilocybin will
be determined for longitudinal outcomes of opioid abstinence, compliance with buprenorphine
maintenance, quality of life, and mood.